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Abstract
Selenium is an essential trace element with potential anti-atherogenic and antioxidant effects. Experimental data suggest that selenium might be
beneficial in the prevention of atherosclerosis and its complications, whereas human epidemiological studies have yielded conflicting results.
Data on hair selenium status in hyperlipidemic patients are still lacking. Therefore, we analysed selenium concentrations by X-ray fluorescence
in the hair of 81 statin-na€ıve patients with newly diagnosed Fredrickson-type IIa and IIb hyperlipoproteinemia and compared their data with 43
healthy volunteers. We also assessed the frequency of other classical risk factors of atherosclerosis. Hair selenium levels were found to be sig-
nificantly higher in hyperlipidemic patients compared with volunteers with normal lipid levels. Also, a significantly increased number of tradi-
tional atherosclerosis risk factors were observed in hyperlipidemic patients with hair selenium concentrations above the median in contrast to
those with below. Our results suggest that high hair selenium status might be associated with adverse blood lipid profile together with an
increased number of traditional risk factors in a selenium-deplete population. These findings warrant further investigations to study the impact
of selenium supplementation on the incidence of cardiovascular events.
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Introduction
Selenium is an essential trace mineral that plays an important role in
several redox, metabolic and inflammatory pathways in mammals.
These processes are also involved in the development of atheroscle-
rosis, in which selenium is suggested to be protective functioning as
a selenocysteine incorporated into selenoproteins. To date, at least 25
selenoproteins have been identified [1]. Epidemiological studies have
previously established the importance of dyslipidemia and oxidative
stress in atherosclerosis, in which oxidized low-density lipoprotein
(ox-LDL) is the major culprit by initiating and maintaining the pro-
gression of the disease [2–4]. Besides hyperlipidemia, other factors
such as hypertension, diabetes mellitus, smoking, obesity and posi-
tive cardiovascular family history present the traditional risk factors
for atherosclerosis resulting in the increased incidence of cardiovas-
cular events in these individuals.
As it is reviewed elsewhere, previous animal-based studies have
shown that—amongst other antioxidants—selenium might reduce oxi-
dative stress and serve as a cytoprotective agent in harmful courses
characterized by enhanced reactive oxygen species (ROS) production
and/or inflammation, all of which are hallmarks of atherosclerosis [5–
7]. Of note, human studies investigating associations between sele-
nium status and atherosclerotic complications have revealed conflicting
data. Population-based studies have reported inverse correlations
between serum selenium levels and cardiovascular mortality [8–10];
however, other investigations have revealed mixed results about the
impact of selenium on incident coronary heart disease [11]. Also,
recent studies have found positive correlation between high levels of
serum selenium and adverse blood lipid profile or diabetes [12–14].
Furthermore, attention has been drawn to the association of high sele-
nium exposure and increased prevalence of hypertension, together with
a more atherogenic lipid profile [15, 16]. It should also be noted that
recent data do not support routine administration of selenium in the
prevention of cardiovascular disease (CVD) [11].
The majority of the above-mentioned studies have measured serum
levels as a marker of selenium status, which one can interpret as a
‘snapshot’ of potential antioxidant capacity provided by this trace ele-
ment. Other techniques, such as toenail or hair selenium levels might
provide an assessment reflecting a longer interval of mineral status in
the human body. However, literature employing these techniques
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specifically aimed to investigate correlations between selenium status
and atherosclerotic complications or lipid profile is scarce: only a few
studies have been performed on toenail selenium status [17–21] and
investigations on hair selenium is even less [22, 23].
To our knowledge, especially in our Central-Eastern European
region, there is no literature published about the hair selenium status
of hyperlipidemic patients. Also, data are lacking regarding the asso-
ciations between hair selenium status and the prevalence of tradi-
tional risk factors of atherosclerosis. Therefore, we aimed to find out
whether hair selenium levels of hyperlipidemic patients would differ
from that of healthy individuals and whether hair selenium status
would show a correlation with the lipid profile or with the presence of
classical risk factors of atherosclerosis in hyperlipidemic patients.
Materials and Methods
Study population
We enrolled 81 consecutive patients with newly diagnosed Fredrickson’s
type IIa or IIb hyperlipoproteinemia that were referred to our lipid clinic
at the 1st Department of Internal Medicine, University of Debrecen Med-
ical and Health Science Center, Hungary; and compared their data with
43 healthy volunteers recruited from our department. All participants
provided their written informed consent. Study design, analyses and
data collection were approved by the institutional ethic board. The study
was carried out according to the World Medical Association Declaration
of Helsinki. Individuals with active liver, kidney and dermatological scalp
diseases, having a diagnosis of type 1 diabetes mellitus or secondary
hypertension were excluded from the study. Also, we did not enrol indi-
viduals with positive history of CVD or taking lipid lowering drugs, vita-
min supplements, selenium or iron containing drugs. None of the
investigated participants used medicated shampoos, bleaches or dyes.
Participants completed a physical examination and a questionnaire
about their medical history. Metric body mass index (BMI) was calcu-
lated as the ratio of the weight measurements in kilogrammes to the
square of the height measurements in metres. After a 10-min. rest, sys-
tolic blood pressure (SBP) and diastolic blood pressure (DBP) were
measured three times 2 min. apart in sitting position. Hypertension was
defined as averages of SBP  140 and/or DBP  90 mmHg or cur-
rently receiving antihypertensive treatment. Patients with the diagnosis
of type 2 diabetes mellitus and receiving any type of anti-diabetic treat-
ment were classified as type 2 diabetic. Smoking was defined if the
patients declared themselves as current smokers or had stopped
<15 years ago. Patients were asked about the health status of their
close relatives including their parents, grandparents, siblings, children
and grandchildren; family history was considered to be positive for
cardiovascular events if the participants had reported incidence any of
ischaemic heart disease, acute coronary syndrome, stroke or peripheral
arterial disease in their relatives.
Lipid measurements
After a 12-hr fast, blood was drawn from cubital veins and sera were
prepared immediately. Reagents were purchased from Roche Diagnos-
tics, Basel, Switzerland. Lipid fractions were measured by automated
methods: serum cholesterol and triglyceride levels were measured by
enzymatic, colorimetric tests (cholesterol oxidase-p-aminophenazone—
CHOD-PAP; and glycerol phosphate oxidase-p-aminophenazone—GPO-
PAP respectively; Modular P-800 Analyzer; Roche/Hitachi, Basel, Swit-
zerland). High-density lipoprotein cholesterol (HDL-C) and low-density
lipoprotein cholesterol (LDL-C) were assessed by homogenous, enzy-
matic, colorimetric assays (HDL-C plus 3rd generation and LDL-C plus
2nd generation respectively). Apolipoprotein A-1 (Apo A-1) and apolipo-
protein B (Apo B) examinations were performed by immunoturbidimetric
assays (Tina-quant a Apolipoprotein A-1 ver. 2 and Tina-quant a Apoli-
poprotein B ver. 2 respectively). The tests were performed according to
the recommendation of the manufacturer.
Selenium measurements
Hair samples were collected with stainless steel scissors from three dif-
ferent places at the occipitonuchal region of the participants, 1 cm away
from the scalp. Samples were washed with deionized water to remove
topical contaminants. The cut ends of the samples were joined to each
other and a 50-mg hair sample was cut and fixed on three special, trace
element-free, nylon filaments. Selenium levels were investigated by
X-ray fluorescence (XRF) analysis with an automated X-ray emission
analytical apparatus of energy resolution of 165 eV (Full Width of Half
Maximum, FWHM = 165 eV, MnKa) as it is described elsewhere
[24–26]. The characteristic radiation of the sample elements was
excited by ring-shaped, 20 GBq and 1000 MBq activity sources contain-
ing Fe-55 and I-125 radioisotopes. The X-ray spectrum of the samples
was analysed by AXIL software, and selenium concentration (parts per
million, ppm) was determined by XRF-BIO software [25].
Statistical analysis
Statistical analysis was performed by the SASTM (SAS Institute Inc.,
Cary, NC, USA) for WindowsTM 8.2 computer software. As hair selenium
and triglyceride levels showed a skewed distribution, we performed a
logarithmic transformation on these variables. Comparisons between
groups were analysed by unpaired t-tests. Wald–Wolfowitz runs test was
applied to analyse the association between log hair selenium and the
presence of risk factors. P < 0.05 was considered statistically significant.
Results
The characteristics of the study population are shown in Table 1.
When compared with the control individuals, serum total choles-
terol, LDL-C and apoB levels were measured to be significantly
higher in the patients (P < 0.001). Serum triglyceride and hair sele-
nium levels showed a skewed distribution with the majority of the
values falling into the lower range; however, these lipid and trace
mineral concentrations appeared to have a high inter-individual var-
iability; therefore we performed a logarithmic transformation on
these variables. As expected, log triglyceride was significantly
higher in hyperlipidemic patients compared with healthy individuals
(P = 0.006). Interestingly, however, log hair selenium was found to
be significantly increased in hyperlipidemic patients in contrast to
healthy individuals (P = 0.0013).
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For further analysis, we divided the hyperlipidemic patients into
two groups on the basis of their hair selenium status: hyperlipidemic
individuals with below and above the median of log hair selenium
respectively (Table 2). Age, BMI and lipid profile were not signifi-
cantly different between the two patient groups.
We also assessed the prevalence of other traditional risk factors
of atherosclerosis across these groups (Table 3). Although none of
the differences have reached statistical significance, smoking was
tended to be more frequent in patients with high selenium levels:
32% of the hyperlipidemic patients were smokers in the high-sele-
nium group, whereas this ratio appeared to be 20% amongst those
who had hair selenium below the median. It should be noted, that hair
selenium concentration did not show a significant difference between
smoking and non-smoking patients (data not shown). We did not find
a similar tendency in the frequencies of other classical risk factors,
such as diabetes mellitus, hypertension or positive familial history.
Assessing the prevalence of all risk factors, we found that hyper-
lipidemic patients in the high-selenium group had significantly more
traditional risk factors of atherosclerosis (P = 0.0025) compared with
those with low hair selenium concentration (Fig. 1). Our results indi-
cate that 50% of the patients with low hair selenium levels possessed
one or more risk factors other than hyperlipidemia, whereas this ratio
was found to be 75% in individuals with hair selenium levels exceed-
ing the median.
Discussion
In this study, we determined hair selenium levels and prevalence of
some major risk factors of atherosclerosis in newly diagnosed hyper-
lipidemic patients. We found increased levels of hair selenium in hy-
perlipidemic patients compared with those with normal lipid levels.
Also, our data indicate that hyperlipidemic patients with hair selenium
levels above the median carry significantly more traditional risk fac-
tors of atherosclerosis in contrast to those hyperlipidemics with hair
selenium levels below the median.
Table 1 Characteristics of the study population
Variables
Controls
(n = 43)
Patients
(n = 81)
P
Age (years) 52.5  14.4 50.5  11.2 n.s.
Gender
(male:female)
20:23 37:44
BMI (kg/m2) 27.7  4.7 27.2  3.5 n.s.
TC (mmol/l) 5.08  0.65 7.42  1.49 <0.001
HDL-C (mmol/l) 1.55  0.65 1.32  0.32 n.s.
LDL-C (mmol/l) 3.03  0.37 5.12  1.25 <0.001
Apo A-1 (g/l) 1.59  0.42 1.53  0.27 n.s.
Apo B (g/l) 0.92  0.21 1.48  0.46 <0.001
Triglyceride
(mmol/l)
1.29 (0.99–1.97) 1.92 (1.47–3.05)
Hair selenium
(ppm)
0.4 (0.08–0.94) 1.03 (0.54–2.06)
Log triglyceride 0.28  0.59 0.81  0.64 0.006
Log hair
selenium
1.369  2.066 0.077  1.144 0.0013
Data are expressed as mean  SD, excluding triglyceride and hair
selenium.
Triglyceride and hair selenium are expressed as median and interquar-
tile range.
P : control individuals versus hyperlipidemic patients.
TC: total cholesterol.
Table 2 Characteristics of hyperlipidemic patients with below and
above the median of log hair selenium
Variables
Below median
(n = 40)
Above median
(n = 41)
P
Age (years) 50.9  11.7 50.1  10.9 n.s.
Gender
(male:female)
17:23 20:21
BMI (kg/m2) 27.0  3.7 27.4  3.3 n.s.
TC (mmol/l) 7.38  1.53 7.45  1.48 n.s.
HDL-C (mmol/l) 1.29  0.33 1.36  0.32 n.s.
LDL-C (mmol/l) 5.17  1.30 5.08  1.22 n.s.
Apo A-1 (g/l) 1.56  0.32 1.49  0.21 n.s.
Apo B (g/l) 1.52  0.52 1.43  0.38 n.s.
Log triglyceride 0.79  0.63 0.84  0.66 n.s.
Data are expressed as mean  SD.
P : patients below the median of log hair selenium versus patients
above the median of log hair selenium.
TC: Total cholesterol.
Table 3 Frequencies of risk factors in hyperlipidemic patients with
below and above the median of log hair selenium
Risk factor
Below
median
(%)
Above
median
(%)
P
Smoking 20 32 n.s
Diabetes mellitus 8 7 n.s.
Hypertension 35 34 n.s.
Positive familial
cardiovascular history
43 46 n.s.
Percentage is expressed as proportion of patients carrying the
observed risk factors in the corresponding group.
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Selenium is an essential trace element that is present in soil and
enters the food chain through plants. Soil selenium concentration is
considered to be low in Europe [27] and high in the United States
[28]. Selenium is also known to have a narrow therapeutic window
with a large inter-individual variability [29]. Selenium is effective
mainly when incorporated into selenoproteins that are involved in
several mechanisms such as defence against ROS, inflammation and
maybe, cancer [1, 5]. Oxidative stress and inflammation are of major
importance in atherosclerosis because they stimulate the formation
of ox-LDL resulting in cholesterol accumulation and foam cell forma-
tion in the vessel wall [2–4, 6, 7]. Selenium supplementation has been
proven to be protective against oxidative injury in human and rodent
endothelial cells, too [30, 31]. Based on the potential of selenium and
selenoproteins to protect against ROS-induced injury, significant
expectations have been raised for the prevention of CVD, however,
data are conflicting.
Despite the promising results of basic research, human studies
have revealed mixed data regarding the association between selenium
exposure and cardiovascular risk. Recent reports have shown that
high selenium exposure—especially in selenium-replete populations
—has been associated with adverse cardio-metabolic outcome, such
as lipid metabolic disorders, together with a higher prevalence of type
2 diabetes mellitus and hypertension. Selenium supplementation has
failed to reduce the risk of CVD in previous trials; and selenium
administration is not advised recently in the prevention of cardiovas-
cular diseases [13–16]. Although these studies have investigated
serum selenium levels and we examined hair selenium concentrations
in patients without manifest CVD, our findings corroborate recent
data indicating that high selenium exposure might be associated with
adverse lipid profile [32]. It should also be considered that we mea-
sured total lipid levels; however, composition of lipoprotein particles
might be modified during the progression of atherosclerosis [33];
therefore, our results cannot be applied automatically to patients with
manifest CVD. Alterations in lipoprotein subpopulations—i.e.
increased pro-inflammatory HDL levels and/or increased oxidized
LDL and small-dense LDL fractions—might modify the outcome of
the atherosclerotic process.
The major form of dietary selenium is selenomethionine that can-
not be synthesized by humans. Selenocysteine is responsible for the
biological activity of selenium and it is also well absorbed. This is also
the case for the inorganic forms of the mineral, selenate and selenite
that are widely used as dietary supplements. Plant foods, cereals,
nuts, meat and seafood are good sources of selenium. Generally, our
study population—both healthy controls and hyperlipidemic patients
—consumed the same diet containing approximately 30% fat and did
not change their dietary habits before serum and hair sampling. It is
presumable that not only the dietary factors are responsible for the
differences found in our study. In addition, increased selenium intake
results in a nonspecific incorporation of selenomethionine into albu-
min and other proteins [34]; however, the role and metabolic activity
of this extra selenium pool are not known yet.
Recent evidence on the impact of selenium on human lipid metab-
olism is poor. Previous studies have demonstrated that small
amounts of selenium are bound to lipoproteins, especially to LDL and
very low-density lipoprotein (VLDL) [35, 36]. Hypercholesterolemia
might affect the synthesis of selenocysteine, which is an essential
compound of selenoproteins, as isopentenylation of selenocysteine
tRNA and one step in the formation of cholesterol require the same
substrate, isopentenyl pyrophosphate [37]. Also, one might speculate
that altered hepatic expression and secretion of selenoprotein P—
which contains approximately 60% of total selenium in plasma and
transports it to other tissues [5]—might contribute to the increased
transport of selenium to the hair in hyperlipidemic patients. Indeed,
serum selenoprotein P levels were recently found to be elevated in
patients with impaired glucose metabolism [38]. However, it is still
unclear, whether the same phenomenon exists in hyperlipidemic
patients. Selenium is also known to modify the activity of lipoprotein
lipase in rats [39]. Altered tissue-specific activation of the enzyme
might also result in elevated hair selenium levels generating an extra
selenium pool.
Considering the monthly hair growth rate, hair samples being cut
1 cm away from the scalp represent the mineral status of the last
3 weeks, approximately, which can be a reliable biomarker of sele-
nium status. Based on the median of log hair selenium levels, further
assessment of the hyperlipidemic patients did not mirror significant
differences in the lipid profile of individuals below or above the med-
ian of the trace mineral, indicating that lipid measurements might be
affected by factors other than selenium exposure in these patients.
Serum selenium level has been reported to be decreased in smok-
ing individuals [40], whereas other studies have shown no relation-
ship between smoking and selenium status [41]. In contrast to these
findings, we observed a tendency of smoking being more frequent in
patients with high hair selenium levels; however, the difference did
not reach statistical significance.
We also found a significantly increased number of traditional
atherosclerosis risk factors in hyperlipidemic patients with hair
selenium concentrations above the median. Patients were slightly
overweight and hyperlipidemic irrespectively of their hair selenium
concentrations, which indicate the presence of other factors in the
background of this result. Glutathione peroxidase (GPx) isoen-
zymes are known to be differently reactive to changes in selenium
status [5] and erythrocyte GPx activity has been reported to be
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Fig. 1 Number of risk factors in hyperlipidemic patients with below and
above the median of log hair selenium (P = 0.0025).
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increased in patients with acute myocardial infarction compared
with population controls [17]; therefore, higher hair selenium con-
centrations and the increased number of risk factors might reflect
an activated and a continuously working antioxidant defence in hy-
perlipidemic patients. Selenium is known to be abundant in food
that is also rich in cholesterol, therefore, other lipid metabolic
alterations—being either pro- or anti-inflammatory, which are not
measured routinely—might lead to an increased hair selenium
level. Taking into consideration that we conducted a cross-sec-
tional study on a limited number of individuals and selenium
showed a high inter-individual variability, we cannot answer if
selenium supplementation would be beneficial for hyperlipidemic
patients to avoid subsequent cardiovascular complications. Indeed,
current evidence does not support selenium supplementation for
the prevention of cardiovascular diseases.
Our findings provide new data regarding hair selenium status in
hyperlipidemic patients with different risk factors in a selenium-
deplete population and reassure previous results that high selenium
levels—together with a higher frequency of traditional risk factors—
might contribute to a development of adverse lipid profile and pro-
gression of atherosclerosis. Further information on hair selenium sta-
tus in a prospective study design is of major importance to assess
the risk of different cardiovascular outcome in hyperlipidemic patients
with various selenium levels.
Acknowledgements
This work has been supported by the TAMOP 4.2.1./B-09/1/KONV-2010-0007
and TAMOP-4.2.2/B-10/1-2010-0024 projects. These projects are cofinanced
by the European Union and the European Social Fund.
Conflicts of interest
The authors confirm that there are no conflicts of interest.
References
1. Kryukov GV, Castellano S, Novoselov SV,
et al. Characterization of mammalian sele-
noproteomes. Science. 2003; 300: 1439–43.
2. Munro JM, Cotran RS. The pathogenesis of
atherosclerosis: atherogenesis and inflam-
mation. Lab Invest. 1988; 58: 249–61.
3. Luc G, Fruchart JC. Oxidation of lipoproteins
and atherosclerosis. Am J Clin Nutr. 1991;
53(1 Suppl.): 206S–9S.
4. Ross R. The pathogenesis of atherosclero-
sis: a perspective for the 1990s. Nature.
1993; 362: 801–9.
5. Reeves MA, Hoffmann PR. The human sele-
noproteome: recent insights into functions
and regulation. Cell Mol Life Sci. 2009; 66:
2457–78.
6. Hulsmans M, Holvoet P. The vicious circle
between oxidative stress and inflammation
in atherosclerosis. J Cell Mol Med. 2010; 14:
70–8.
7. L€u JM, Lin PH, Yao Q, et al. Chemical and
molecular mechanisms of antioxidants:
experimental approaches and model sys-
tems. J Cell Mol Med. 2010; 14: 840–60.
8. Salonen JT, Alfthan G, Huttunen JK, et al.
Association between cardiovascular death
and myocardial infarction and serum sele-
nium in a matched-pair longitudinal study.
Lancet. 1982; 2: 175–9.
9. Lubos E, Sinning CR, Schnabel RB, et al.
Serum selenium and prognosis in cardiovas-
cular disease: results from the AtheroGene
study. Atherosclerosis. 2010; 209: 271–7.
10. Eaton CB, Abdul Baki AR, Waring ME, et al.
The association of low selenium and renal
insufficiency with coronary heart disease
and all-cause mortality: NHANES III follow-
up study. Atherosclerosis. 2010; 212: 689–
94.
11. Flores-Mateo G, Navas-Acien A, Pastor-
Barriuso R, et al. Selenium and coronary
heart disease: a meta-analysis. Am J Clin
Nutr. 2006; 84: 762–73.
12. Stranges S, Laclaustra M, Ji C, et al.
Higher selenium status is associated with
adverse blood lipid profile in British adults.
J Nutr. 2010; 140: 81–7.
13. Laclaustra M, Stranges S, Navas-Acien A,
et al. Serum selenium and serum lipids in
US adults: National Health and Nutrition
Examination Survey (NHANES) 2003–2004.
Atherosclerosis. 2010; 210: 643–8.
14. Stranges S, Galletti F, Farinaro E, et al.
Associations of selenium status with cardio-
metabolic risk factors: an 8-year follow-up
analysis of the Olivetti Heart Study. Athero-
sclerosis. 2011; 217: 274–8.
15. Laclaustra M, Navas-Acien A, Stranges S,
et al. Serum selenium concentrations and
hypertension in the US Population. Circ
Cardiovasc Qual Outcomes. 2009; 2: 369–
76.
16. Bleys J, Navas-Acien A, Stranges S, et al.
Serum selenium and serum lipids in US
adults. Am J Clin Nutr. 2008; 88: 416–23.
17. Kok FJ, Hofman A, Witteman JC, et al.
Decreased selenium levels in acute myocar-
dial infarction. JAMA. 1989; 261: 1161–4.
18. Kardinaal AF, Kok FJ, Kohlmeier L, et al.
Association between toenail selenium and
risk of acute myocardial infarction in Euro-
pean men. The EURAMIC Study. European
antioxidant myocardial infarction and breast
cancer. Am J Epidemiol. 1997; 145: 373–9.
19. Yoshizawa K, Ascherio A, Morris JS, et al.
Prospective study of selenium levels in toe-
nails and risk of coronary heart disease in
men. Am J Epidemiol. 2003; 158: 852–60.
20. Xun P, Liu K, Morris JS, et al. Longitudinal
association between toenail selenium levels
and measures of subclinical atherosclerosis:
the CARDIA trace element study. Atheroscle-
rosis. 2010; 210: 662–7.
21. Xun P, Liu K, Morris JS, et al. Associations
of toenail selenium levels with inflammatory
biomarkers of fibrinogen, high-sensitivity c-
reactive protein, and interleukin-6: the CAR-
DIA Trace Element Study. Am J Epidemiol.
2010; 171: 793–800.
22. Thimaya S, Ganapathy SN. Selenium in
human hair in relation to age, diet, patholog-
ical condition and serum levels. Sci Total
Environ. 1982; 24: 41–9.
23. Djujic IS, Jozanov-Stankov ON, Milovac M,
et al. Bioavailability and possible benefits of
wheat intake naturally enriched with sele-
nium and its products. Biol Trace Elem Res.
2000; 77: 273–85.
24. Bacso J, Uzonyi I. Development of an auto-
matic sample changer for XRF measure-
ments. Izotopenpraxis - Isotopes Environ
Health Stud. 1988; 24: 72–3.
25. Uzonyi I. A new XRF method for the analysis
of biological samples. Izotopenpraxis - Iso-
topes Environ Health Stud. 1988; 24: 79–81.
26. Shenberg C, Mantel M, Izak-Biran T, et al.
Rapid and simple determination of selenium
and other trace elements in very small blood
354 ª 2013 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
samples by XRF. Biol Trace Elem Res. 1988;
16: 87–95.
27. Brown KM, Arthur JR. Selenium, selenopro-
teins and human health: a review. Public
Health Nutr. 2001; 4: 593–9.
28. Bleys J, Navas-Acien A, Guallar E. Serum
selenium and diabetes in US adults. Diabetes
Care. 2007; 30: 829–34.
29. Whanger P, Vendeland S, Park YC, et al.
Metabolism of subtoxic levels of selenium in
animals and humans. Ann Clin Lab Sci.
1996; 26: 99–113.
30. Thomas JP, Geiger PG, Girotti AW. Lethal
damage to endothelial cells by oxidized low
density lipoprotein: role of selenoperoxidas-
es in cytoprotection against lipid hydroper-
oxide- and iron-mediated reactions. J Lipid
Res. 1993; 34: 479–90.
31. Huang K, Liu H, Chen Z, et al. Role of
selenium in cytoprotection against cho-
lesterol oxide-induced vascular damage
in rats. Atherosclerosis. 2002; 162: 137–
44.
32. Stranges S, Tabak AG, Guallar E, et al.
Selenium status and blood lipids: the cardio-
vascular risk in Young Finns study. J Intern
Med. 2011; 270: 469–77.
33. Schultz JR, Verstuyft JG, Gong EL, et al.
Protein composition determines the anti-ath-
erogenic properties of HDL in transgenic
mice. Nature. 1993; 365: 762–4.
34. Daniels LA. Selenium metabolism and bio-
availability. Biol Trace Elem Res. 1996; 54:
185–99.
35. Ducros V, Laporte F, Belin N, et al. Sele-
nium determination in human plasma lipo-
protein fractions by mass spectrometry
analysis. J Inorg Biochem. 2000; 81: 105–9.
36. Burk RF. Invivo Se-75 binding to human
plasma-proteins after administration of Se-
75 O3 2-. Biochim Biophys Acta. 1974; 372:
255–65.
37. Moosmann B, Behl C. Selenoprotein synthe-
sis and side-effects of statins. Lancet. 2004;
363: 892–4.
38. Yang SJ, Hwang SY, Choi HY, et al. Serum
selenoprotein P levels in patients with type 2
diabetes and prediabetes: implications for
insulin resistance, inflammation, and athero-
sclerosis. J Clin Endocrinol Metab. 2011; 96:
E1325–9.
39. Ueki H, Ohkura Y, Motoyashiki T, et al.
Increase in lipoprotein lipase activity in iso-
lated rat adipose tissue by selenate. Biol
Pharm Bull. 1993; 16: 6–10.
40. Wei W, Kim Y, Boudreau N. Association of
smoking with serum and dietary levels of an-
tioxidants in adults: NHANES III, 1988–1994.
Am J Public Health. 2001; 91: 258–64.
41. Robinson MF, Campbell DR, Sutherland
WH, et al. Selenium and risk factors for car-
diovascular disease in New Zealand. N Z
Med J. 1983; 96: 755–7.
ª 2013 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. 355
J. Cell. Mol. Med. Vol 17, No 3, 2013
